does semaglutide cause tachycardia Heart Palpitations? Evidence and Management increased heart rate with GLP1

Universidad de Barcelona, Spain Despite recent advancements in the field of neuro-ophthalmology, the rising rates of neurological and ophthalmological conditions, mismatches between supply and demand of clinicians, and an aging population underscore the urgent need to explore new therapeutic approaches within the field

The approval could help spur a turnaround for Novo after a rocky year of sliding shares, profit warnings and slowing sales of its injectable Wegovy amid intense competition from Lilly and pressure from compounded versions

Retrieved February 26, 2024

Tiecke E, Rainisio M, Eisenberg E, Wainstein J, Kaplan E, Silverberg M, et al

Morgan Stanley Research estimates that the global market for GLP-1 drugs could reach $190 billion by 2035, more than double the $79 billion in total sales recorded in 2025, with growth supported by oral treatment formats, broader insurance coverage, international market expansion, and new therapeutic use cases